|
TEL: +32 16 58 90 45
Fax :+ 32 16 50 90 45
GENTAUR Europe
tel+32 2 732 5688
fax+32 2 732 4414
Av.
de l' Armée 68
B-1040 BRUSSELS
BELGIUM
GENTAUR France
tel 01 43 25
01 50
fax01 43 25
01 60
9, rue
Lagrange
75005 PARIS
FRANCE
GENTAUR Italy
tel 02 36 00
65 93
fax 02 36 00
65 94
20135 MILANO
ITALY
GENTAUR Germany
tel +49 241
6085 13140
fax +49 241
6085 33033
Forckenbeckstraße 6,
D-52074
Aachen
GERMANY
| |
Price : 5 slide for 600 €
| CH1 Human larynx and pharynx cancer |
| |
|
|
|
|
|
|
| |
Age |
Sex |
Location |
Diagnosis |
TNM |
Stage |
| 1 |
43 |
M |
larynx, pyriform sinus |
SCC*, moderately differentiated |
T4N2M0 |
ⅣA |
| 2 |
55 |
M |
larynx, subglottic |
SCC, moderately differentiated |
T4N0M0 |
ⅣA |
| 3 |
72 |
M |
larynx, supraglottic |
SCC, moderately differentiated |
T3N0M0 |
Ⅲ |
| 4 |
63 |
M |
esophagus |
SCC, basaloid type |
T4N0M0 |
ⅣA |
| 5 |
67 |
M |
larynx, transglottic |
SCC, well differentiated |
T4N2bM0 |
ⅣA |
| 6 |
63 |
M |
larynx, pyriform sinus |
SCC, moderately differentiated |
T4N2cM0 |
ⅣA |
| 7 |
60 |
M |
larynx, supraglottic |
SCC, moderately differentiated |
T4N2cM0 |
ⅣA |
| 8 |
61 |
M |
larynx, glottic |
SCC, moderately differentiated |
T4N0M0 |
ⅣA |
| 9 |
66 |
M |
larynx, glottic |
SCC, moderately differentiated |
T4N0M0 |
ⅣA |
| 10 |
56 |
M |
larynx, glottic |
SCC, well differentiated |
T1N0M0 |
Ⅰ |
| 11 |
62 |
M |
larynx, supraglottic |
SCC, moderately differentiated |
T3N2M0 |
ⅣA |
| 12 |
56 |
M |
larynx, pyriform sinus |
SCC, moderately differentiated |
T4N2bM0 |
ⅣA |
| 13 |
54 |
M |
larynx, supraglottic |
SCC, well differentiated |
T3N0M0 |
Ⅲ |
| 14 |
48 |
M |
larynx, transglottic |
SCC, well differentiated |
T3N0M0 |
Ⅲ |
| 15 |
61 |
M |
larynx, supraglottic |
SCC, well differentiated |
T3N0M0 |
Ⅲ |
| 16 |
66 |
M |
soft tissue of neck |
SCC, well differentiated of hypopharynx |
T4N0M0 |
Ⅳ |
| 17 |
51 |
M |
larynx, supraglottic |
SCC, moderately differentiated |
T4N2cM0 |
ⅣA |
| 18 |
46 |
M |
soft tissue, neck |
SCC of hypopharynx |
T2N3M0 |
ⅣB |
| 19 |
52 |
M |
larynx, supraglottic |
SCC, moderately differentiated |
T2N0M0 |
Ⅱ |
| 20 |
52 |
F |
Nasal cavity |
undifferentiated carcinoma |
T4NxM0 |
ⅣA |
| 21 |
64 |
M |
larynx, transglottic |
basaloid SCC |
T3N1M0 |
Ⅲ |
| 22 |
28 |
F |
lymph node |
undifferentiated carcinoma from nasopharynx |
T1N2cMx |
0 |
| 23 |
63 |
M |
Nasopharynx |
undifferentiated carcinoma |
TxN2M1 |
ⅣC |
| 24 |
77 |
M |
Neck |
undifferentiated carcinoma |
TxN2M0 |
ⅣA |
| 25 |
51 |
M |
larynx, transglottic |
SCC, well differentiated |
T4N2M0 |
ⅣA |
| 26 |
51 |
M |
hypopharynx |
SCC, moderately differentiated |
TxN1M0 |
Ⅲ |
| 27 |
59 |
M |
nasal cavity |
SCC, poorly differentiated |
T4N0M0 |
ⅣA |
| 28 |
55 |
M |
larynx, subglottic |
SCC, moderately differentiated |
T3N0M0 |
Ⅲ |
| 29 |
60 |
M |
larynx, transglottic |
Larynx, SCC, well differentiated |
T4N0M0 |
ⅣA |
| 30 |
70 |
M |
oropharynx |
undifferentiated carcinoma |
T1N2aM0 |
ⅣA |
| 31 |
55 |
|
